In the overall study population, and in those considered to have cardiac involvement (based on the prespecified definition used in the post hoc APOLLO analysis), treatment with vutrisiran was associated with beneficial changes in NT-proBNP and a nominally significant beneficial change in stroke volume compared with placebo.
← all excerpts
The Last Decade in Cardiac Amyloidosis: Advances in Understanding Pathophysiology, Diagnosis and Quantification, Prognosis, Treatment Strategies, and Monitoring Response.
1
—
—